Literature DB >> 7402252

Hypocitraturia in patients with gastrointestinal malabsorption.

D Rudman, J L Dedonis, M T Fountain, J B Chandler, G G Gerron, G A Fleming, M H Kutner.   

Abstract

We measured serum and urinary citrate, oxalate, calcium, and magnesium in 22 normal subjects and in 16 patients with malabsorption. The patients had subnormal levels of serum citrate and magnesium during fasting, subnormal 24-hour levels of urinary citrate, magnesium, and calcium, and excessive levels of urinary oxalate. Daily citrate excretion averaged only 15 per cent of normal. The hypocitraturia in the patients resulted from a subnormal filtered load of citrate and abnormally high net tubular reabsorption of the anion. An oral citrate supplement raised both the serum concentration and the filtered load of citrate to normal fasting values, but net tubular reabsorption remained abnormally high and urinary excretion abnormally low. Intramuscular magnesium sulfate, which corrected the hypomagnesemia and hypomagnesuria, had no effect on serum citrate or its filtered load. Nevertheless the injection restored net tubular reabsorption of citrate to normal and partially improved the hypocitraturia. Full correction of the hypocitraturia was achieved by combined treatment with oral citrate and intramuscular magnesium sulfate. Hypocitraturia may contribute to the formation of oxalate stones in these patients, and therefore our treatment may help to prevent this complication.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7402252     DOI: 10.1056/NEJM198009183031201

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  24 in total

1.  The many roles of oxalate in nature.

Authors:  Lynwood H Smith
Journal:  Trans Am Clin Climatol Assoc       Date:  2002

2.  Hypocitraturia in common bottlenose dolphins (Tursiops truncatus): assessing a potential risk factor for urate nephrolithiasis.

Authors:  Stephanie K Venn-Watson; Forrest I Townsend; Risa L Daniels; Jay C Sweeney; Jim W McBain; Leigh J Klatsky; Christie L Hicks; Lydia A Staggs; Teri K Rowles; Lori H Schwacke; Randall S Wells; Cynthia R Smith
Journal:  Comp Med       Date:  2010-04       Impact factor: 0.982

Review 3.  Treatment of enteric hyperoxaluria.

Authors:  J Harper; M A Mansell
Journal:  Postgrad Med J       Date:  1991-03       Impact factor: 2.401

4.  Guidelines for management of patients with a short bowel.

Authors:  J Nightingale; J M Woodward
Journal:  Gut       Date:  2006-08       Impact factor: 23.059

5.  Evidence for epistatic interaction between VDR and SLC13A2 genes in the pathogenesis of hypocitraturia in recurrent calcium oxalate stone formers.

Authors:  Domenico Rendina; Gianpaolo De Filippo; Fernando Gianfrancesco; Riccardo Muscariello; Michele Schiano di Cola; Pasquale Strazzullo; Teresa Esposito
Journal:  J Nephrol       Date:  2016-09-17       Impact factor: 3.902

6.  Urinary factors of kidney stone formation in patients with Crohn's disease.

Authors:  H Böhles; O J Beifuss; U Brandl; J Pichl; Z Akçetin; L Demling
Journal:  Klin Wochenschr       Date:  1988-02-01

7.  Enteric hyperoxaluria, recurrent urolithiasis, and systemic oxalosis in patients with Crohn's disease.

Authors:  Renate Hueppelshaeuser; Gerd E von Unruh; Sandra Habbig; Bodo B Beck; Stephan Buderus; Albrecht Hesse; Bernd Hoppe
Journal:  Pediatr Nephrol       Date:  2012-02-25       Impact factor: 3.714

Review 8.  Urolithiasis in children: current medical management.

Authors:  J Laufer; H Boichis
Journal:  Pediatr Nephrol       Date:  1989-07       Impact factor: 3.714

9.  Proton-pump inhibitors associated with decreased urinary citrate excretion.

Authors:  Parth M Patel; Alexander M Kandabarow; Eseosa Aiwerioghene; Enrique Blanco-Martinez; Spencer Hart; David J Leehey; Ahmer Farooq; Kristin G Baldea; Thomas M T Turk
Journal:  Int Urol Nephrol       Date:  2020-11-18       Impact factor: 2.370

Review 10.  Urine citrate and renal stone disease.

Authors:  H Goldberg; L Grass; R Vogl; A Rapoport; D G Oreopoulos
Journal:  CMAJ       Date:  1989-08-01       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.